Tykerb Related Published Studies
Well-designed clinical trials related to Tykerb (Lapatinib)
Target-specific, histology-independent, randomized discontinuation study of
lapatinib in patients with HER2-amplified solid tumors. [2012]
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. [2011.08.23]
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. [2011.08]
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. [2011.03.01]
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. [2010.08.01]
Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer. [2010.08]
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. [2010.04]
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. [2010.03.15]
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. [2010.03.01]
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. [2010]
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving
lapatinib in combination with paclitaxel as first-line treatment for metastatic
breast cancer. [2010]
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. [2009.11.20]
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. [2009.11.20]
Lapatinib for the treatment of HER2-overexpressing breast cancer. [2009.10]
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. [2009.10]
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. [2009.08.20]
Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. [2009.04]
Effects of food on the relative bioavailability of lapatinib in cancer patients. [2009.03.10]
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. [2008.12.01]
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. [2008.12]
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. [2008.09.02]
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. [2008.06.20]
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. [2008.05.10]
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). [2008.02]
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. [2006.12.28]
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. [2005.08.10]
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. [2005.04.10]
Well-designed clinical trials possibly related to Tykerb (Lapatinib)
A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck. [2011.04]
Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias. [2010.01]
Lessons learned from independent central review. [2009.01]
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. [2005.01]
Other research related to Tykerb (Lapatinib)
Overall survival benefit with lapatinib in combination with trastuzumab for
patients with human epidermal growth factor receptor 2-positive metastatic breast
cancer: final results from the EGF104900 Study. [2012]
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal
growth factor receptor 2-positive operable breast cancer: results of the
randomized phase II CHER-LOB study. [2012]
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib
and capecitabine in HER2-positive metastatic breast cancer. [2012]
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. [2011.12]
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study. [2011.10.28]
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer. [2011.10.18]
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. [2011.10.11]
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. [2011.09.13]
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer(,). [2011.07.22]
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. [2011.07]
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. [2011.06.15]
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. [2011.06.08]
[Tykerb for breast cancer]. [2011.06]
Lapatinib-induced hepatitis: a case report. [2011.05.14]
Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer. [2011.05]
Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans. [2011.05]
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. [2011.05]
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe. [2011]
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the
breast in a randomized, placebo-controlled presurgical trial. [2011]
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or
advanced solid tumors. [2011]
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of
life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. [2011]
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. [2010.09.22]
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. [2010.08]
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. [2010.07.30]
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. [2010.07.10]
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. [2010.06.20]
Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. [2010.06.01]
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. [2010.06]
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. [2010.05.01]
Lapatinib side-effect management. [2010.04]
Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer. [2010]
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. [2010]
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. [2010]
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with
pazopanib plus lapatinib combination therapy in patients with advanced and
recurrent cervical cancer. [2010]
Randomized phase II multicenter trial of two schedules of lapatinib as first- or
second-line monotherapy in patients with advanced or metastatic non-small cell
lung cancer. [2010]
Randomized study of Lapatinib alone or in combination with trastuzumab in women
with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. [2010]
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. [2009.10.08]
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer. [2009.09.28]
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. [2009.09.15]
Lapatinib: A competitor or companion to trastuzumab? [2009.09.10]
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. [2009.08]
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. [2009.07.15]
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. [2009.07.01]
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. [2009.06.05]
Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer. [2009.06]
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. [2009.06]
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. [2009.06]
Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. [2009.04]
Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. [2009.03.01]
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. [2009.02.15]
Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients. [2009.02.02]
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. [2009.02.01]
Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors. [2009.02]
Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. [2009.01.26]
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. [2009.01.20]
Degarelix. [2009]
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. [2008.12.01]
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. [2008.12.01]
Lapatinib therapy for patients with advanced renal cell carcinoma. [2008.11]
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. [2008.10.27]
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. [2008.10.01]
Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. [2008.10]
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. [2008.10]
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. [2008.10]
Lapatinib and ixabepilone for the treatment of metastatic breast cancer. [2008.10]
Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. [2008.09.15]
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. [2008.09]
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. [2008.08]
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. [2008.07.15]
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. [2008.07.10]
|
